exploratory outcome study of ibogaine assisted therapy in 20 chemically dependent persons n.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Exploratory Outcome Study of Ibogaine-Assisted Therapy in 20 Chemically-Dependent Persons PowerPoint Presentation
Download Presentation
Exploratory Outcome Study of Ibogaine-Assisted Therapy in 20 Chemically-Dependent Persons

Loading in 2 Seconds...

play fullscreen
1 / 23

Exploratory Outcome Study of Ibogaine-Assisted Therapy in 20 Chemically-Dependent Persons - PowerPoint PPT Presentation


  • 120 Views
  • Uploaded on

Exploratory Outcome Study of Ibogaine-Assisted Therapy in 20 Chemically-Dependent Persons. Valerie Mojeiko Multidisciplinary Association for Psychedelic Studies (MAPS) www.maps.org. Tabernanthe Iboga. Howard Lotsof. Subjective Effects. Psychedelic that produces a dreamlike state

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Exploratory Outcome Study of Ibogaine-Assisted Therapy in 20 Chemically-Dependent Persons' - eileen


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
exploratory outcome study of ibogaine assisted therapy in 20 chemically dependent persons

Exploratory Outcome Study of Ibogaine-Assisted Therapy in 20 Chemically-Dependent Persons

Valerie Mojeiko

Multidisciplinary Association for Psychedelic Studies (MAPS) www.maps.org

slide2

Tabernanthe Iboga

Ibogaine Outcome Study, V. Mojeiko

slide5

Howard Lotsof

Ibogaine Outcome Study, V. Mojeiko

subjective effects
Subjective Effects
  • Psychedelic that produces a dreamlike state
  • Review of memories
  • Experience lasts several days
  • Many find it unpleasant, not a recreational drug
  • Some experience psychological material related to addiction
  • Greatly reduces physical and psychological withdrawal symptoms from heroin, methadone, other drugs

Ibogaine Outcome Study, V. Mojeiko

neurotransmitter activities
Neurotransmitter Activities
  • Novel mechanism of action
  • Complex interactions between multiple neurotransmitter systems
  • Mu-opiod agonist; NMDA antagonist; kappa opioid agonist; serotonin 5ht2a agonist; serotonin uptake inhibitor; 5ht3 agonist; dopamine uptake inhibitor; sigma opioid receptor agonist…

Ibogaine Outcome Study, V. Mojeiko

where do addicts take ibogaine
Where do addicts take ibogaine?

Ibogaine Outcome Study, V. Mojeiko

slide9

Hotel Rooms

Ibogaine Outcome Study, V. Mojeiko

slide10

At Home

Ibogaine Outcome Study, V. Mojeiko

slide11

Iboga Therapy House, Canada

Ibogaine Outcome Study, V. Mojeiko

existing treatment facilities providing detoxification not collecting information
Existing treatment facilities providing detoxification--not collecting information…
  • How well does it work? How safe is it?
  • What percentage of people benefit and to what degree?
  • How can these treatments be improved?
  • Should formal studies be conducted?

MAPS’ Role: Evaluating program, providing feedback, and collecting data for research

Ibogaine Outcome Study, V. Mojeiko

preliminary data june 2004 iboga therapy house 2wks 1yr after tx avg 6 months
Preliminary Data: June 2004: Iboga Therapy House: 2wks-1yr after tx (avg. 6 months)
  • 20 subjects
  • 6 of 7 treated for Cocaine/Crack abstinent (86%)
  • 3 of 8 treated for opiates abstinent (38%)
  • 4/5 treated for other substances abstinent (80%)

Ibogaine Outcome Study, V. Mojeiko

exploratory outcome study
Exploratory Outcome Study
  • Seeking to obtain basic preliminary data
  • Not a controlled study, but is representative since including 20 Subjects treated consecutively
  • One-year series of questionnaires and interviews from 20 subjects verified by interview with significant others
  • Harm reduction model: looking at abstinence as well as non-abstinence outcomes, trying to differentiate between abuse and controlled use

Ibogaine Outcome Study, V. Mojeiko

asi addiction severity index
ASI-Addiction Severity Index
  • Semi-structured 1 hour interview
  • Scores on 7 subscales: medical status, employment and support, drug use, alcohol use, legal status, family/social status, and psychiatric status
  • Been used extensively on a wide variety of outcome studies

Ibogaine Outcome Study, V. Mojeiko

peak experience profile pep
Peak Experience Profile (PEP)
  • Measures the psychedelic experience
  • 180 items; one composite score; 16 subscores
  • Scores for peaks (highs) and nadirs (lows)

Ibogaine Outcome Study, V. Mojeiko

measures
Measures
  • Addiction Severity Index (primary variable)
  • Peak Experience Profile
  • Beck Depression and Anxiety Inventories
  • Subjective and Objective Opiate Withdrawal Scales (SOWS/OOWS)
  • Pain and Craving Scales

Ibogaine Outcome Study, V. Mojeiko

process
Process
  • All interviews are conducted by evaluation coordinator
  • Baseline in person; follow-up by phone
  • Each interview takes about an hour or two
  • Valerie organizes and analyzes data

Ibogaine Outcome Study, V. Mojeiko

slide20

Schedule for Outcome Measures

i=Intake; P=Post-treatment; W2=Week 2; 1-12=Months 1-12

Ibogaine Outcome Study, V. Mojeiko

challenges
Challenges
  • No drug testing
  • Difficulty of remaining in contact during follow-up
  • Check-in with significant other addresses these concerns

Ibogaine Outcome Study, V. Mojeiko

progress
Progress
  • End of protocol design and training phase
  • Began study at Ibogaine Association; ended prematurely
  • Assisting Iboga Therapy House in obtaining grant from Health Canada
  • Partial funding obtained from private donors for study, Iboga Therapy House seeking additional funding for operating costs

Ibogaine Outcome Study, V. Mojeiko

goals
Goals
  • Obtain basic information about outcomes in underground clinics
  • Provide feedback to improve services; help win funding from Canadian government; increase safety
  • Ideally lead to placebo-controlled double-blind studies
  • Ibogaine available to drug addicts in a safe, supportive, and humane setting

Ibogaine Outcome Study, V. Mojeiko